![]() ![]() This study confirms the safety of NTD, even in patients treated with anticoagulant drugs. However, GI side effects are frequent and NTD dose adjustment may be necessary to retain the drug in IPF patients. In a real-life clinical scenario, NTD may stabilize the FVC values in IPF patients. One patient died within the first 6 months and two subjects died within the first 12 months. Bleeding episodes have also not been reported in patients taking anticoagulant therapy. Among individuals that suspended the dosage, 14 (78%) had gastrointestinal (GI) collateral effects (i.e., diarrhea being the most common complaint (67%), followed by nausea/vomiting (17%) and weight loss (6%). In the cohort, 18 (32%) individuals suspended NTD and 10 (18%) reduced the dosage. No significant variation was observed for FVC. We identified a significant variation between baseline and 12 months for FEV1 ( p = 0.039) and for DLCO ( p = 0.018). For FVC and FEV1 we found no significant change between baseline and 6 months, but for DLCO we observed a decrease ( p = 0.012). At enrollment, HRCT showed an UIP pattern in 45 (80%) and a NSIP in 11 (20%) patients. In total, 56 IPF patients (34% female and 66% male, mean onset age: 71 ± 11 years, mean age at baseline: 74 ± 9 years) treated with NTD were identified. ![]() The following parameters were recorded: IPF clinical features, NTD tolerability, and pulmonary function tests (PFT) (i.e., Forced Vital Capacity (FVC) and carbon monoxide diffusing capacity (DLCO)). Clinical data of patients with IPF treated with NTD at our center were retrospectively evaluated at baseline and at 6 and 12 months after the introduction of NTD. ![]() Our objective was to examine the safety profile and efficacy of nintedanib even in subjects treated with anticoagulants. Here we describe the experience of NTD use in IPF in a real-life setting. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease (ILD) in IPF. Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of ~3 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |